Literature DB >> 10559313

A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm).

M A Accola1, A A Bukovsky, M S Jones, H G Göttlinger.   

Abstract

Vpr is a small accessory protein of human and simian immunodeficiency viruses (HIV and SIV) that is specifically incorporated into virions. Members of the HIV-2/SIV(sm)/SIV(mac) lineage of primate lentiviruses also incorporate a related protein designated Vpx. We previously identified a highly conserved L-X-X-L-F sequence near the C terminus of the p6 domain of the Gag precursor as the major virion association motif for HIV-1 Vpr. In the present study, we show that a different leucine-containing motif (D-X-A-X-X-L-L) in the N-terminal half of p6(gag) is required for the incorporation of SIV(mac) Vpx. Similarly, the uptake of SIV(mac) Vpr depended primarily on the D-X-A-X-X-L-L motif. SIV(mac) Vpr was unstable when expressed alone, but its intracellular steady-state levels increased significantly in the presence of wild-type Gag or of the proteasome inhibitor lactacystin. Collectively, our results indicate that the interaction with the Gag precursor via the D-X-A-X-X-L-L motif diverts SIV(mac) Vpr away from the proteasome-degradative pathway. While absent from HIV-1 p6(gag), the D-X-A-X-X-L-L motif is conserved in both the HIV-2/SIV(sm)/SIV(mac) and SIV(agm) lineages of primate lentiviruses. We found that the incorporation of SIV(agm) Vpr, like that of SIV(mac) Vpx, is absolutely dependent on the D-X-A-X-X-L-L motif, while the L-X-X-L-F motif used by HIV-1 Vpr is dispensable. The similar requirements for the incorporation of SIV(mac) Vpx and SIV(agm) Vpr provide support for their proposed common ancestry.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559313      PMCID: PMC113050     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.

Authors:  F Re; D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat.

Authors:  L Wang; S Mukherjee; F Jia; O Narayan; L J Zhao
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

6.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

Authors:  S R Bartz; M E Rogel; M Emerman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr.

Authors:  E Kondo; H G Göttlinger
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product.

Authors:  Y Refaeli; D N Levy; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.

Authors:  M Bouhamdan; S Benichou; F Rey; J M Navarro; I Agostini; B Spire; J Camonis; G Slupphaug; R Vigne; R Benarous; J Sire
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more
  53 in total

1.  The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells.

Authors:  H A Pancio; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Simian immunodeficiency virus Vpx is imported into the nucleus via importin alpha-dependent and -independent pathways.

Authors:  Prabhat K Singhal; P Rajendra Kumar; Malireddi R K Subba Rao; Mahesh Kyasani; Sundarasamy Mahalingam
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or Gag.

Authors:  Sergei Popov; Bettina Strack; Victor Sanchez-Merino; Elena Popova; Heike Rosin; Heinrich G Göttlinger
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

5.  Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages.

Authors:  Mikako Fujita; Masami Otsuka; Masami Miyoshi; Boonruang Khamsri; Masako Nomaguchi; Akio Adachi
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

Review 6.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

7.  Variation of two primate lineage-specific residues in human SAMHD1 confers resistance to N terminus-targeted SIV Vpx proteins.

Authors:  Wei Wei; Haoran Guo; Qimeng Gao; Richard Markham; Xiao-Fang Yu
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

8.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  Degradation of SAMHD1 by Vpx Is Independent of Uncoating.

Authors:  Paula Jáuregui; Eric C Logue; Megan L Schultz; Stephanie Fung; Nathaniel R Landau
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

10.  Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells.

Authors:  Caroline Goujon; Vanessa Arfi; Thomas Pertel; Jeremy Luban; Julia Lienard; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.